Amova Asset Management Americas, Inc. has updated its position in Arcturus Therapeutics Holdings Inc., revealing a 5.9% stake in the company. This filing, submitted on November 13, 2026, is significant as it showcases the increasing interest from investment firms in the pharmaceutical sector, particularly in biotech companies like Arcturus.

Arcturus Therapeutics Holdings Inc., based in San Diego, California, specializes in pharmaceutical preparations, as indicated by its SIC code 2834. The company is publicly traded on the Nasdaq under the ticker ARCT. This filing is part of a series of recent disclosures, with the last notable filings including a 10-Q on November 5, 2026, and an 8-K on the same date.

The recent Schedule 13G/A filing indicates that Amova holds a total of 1,689,107 shares of Arcturus, with shared voting power over 1,459,991 shares. The filing also notes that these shares were acquired in the ordinary course of business and not for the purpose of influencing control over the company. This is the third amendment to their previous filings, reflecting changes in their ownership structure since their last update.

This update could impact various stakeholders, including current shareholders and potential investors, as it highlights the growing interest in Arcturus from institutional investors. The pharmaceutical industry continues to attract significant attention, and such investments may signal confidence in Arcturus's future prospects.

Details were not available in the SEC filing regarding what steps Amova may take next or how this stake might influence Arcturus's strategic direction. However, the filing does indicate that Amova is acting as an investment adviser, suggesting they may continue to monitor their investment closely.